To identify potential drugs that might sensitize abemaciclib, we employed FDA-approved small-molecule protein kinase inhibitors to co-treat with abemaciclib in lung cancer cells (Roskoski, 2020), and found that mTOR inhibitor, rapamycin and FLT3 inhibitor, gilteritinib enhanced the cytotoxicity of abemaciclib (Supplementary Figure S3C). Here, MTOR is linked to lung carcinoma.